Aspirin

Generic Name: Aspirin

Brand Names: Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala

Drug Type: Small Molecule

Chemical Formula: C_₉H_₈O_₄

CAS Number: 50-78-2

Unique Ingredient Identifier: R16CO5Y76E

Background: Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .
...

Indication: Pain, fever, and inflammation
...

Associated Conditions: Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke

Associated Therapies: Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Clinical Trials

Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance

Not Applicable

Completed

Conditions: Impaired Glucose Tolerance
Prediabetic State

Interventions: Drug: Aspirin
Drug: Olmesartan
Drug: Placebo
Drug: Alpha lipoic acid

First Posted Date: 2005-07-22

Last Posted Date: 2013-12-05

Lead Sponsor: Emory University

Target Recruit Count: 84

Registration Number: NCT00122447

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
Grady Health System, Atlanta, Georgia, United States

Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial

Phase 4

Completed

Conditions: Arteriosclerosis
Coronary Disease
Diabetes Mellitus, Type 2

Interventions: Drug: No aspirin
Drug: Aspirin

First Posted Date: 2005-05-10

Last Posted Date: 2016-11-02

Lead Sponsor: Kumamoto University

Target Recruit Count: 2539

Registration Number: NCT00110448

Locations: 🇯🇵
First Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan
🇯🇵
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER)

Phase 2

Completed

Conditions: Transient Ischemic Attack
Stroke

First Posted Date: 2005-04-27

Last Posted Date: 2008-04-08

Lead Sponsor: University of Calgary

Target Recruit Count: 500

Registration Number: NCT00109382

Locations: 🇨🇦
Foothills Medical Centre, Calgary, Alberta, Canada
🇨🇦
Universtiy of Alberta Walter MacKenzie Health Sciences Centre, Edmonton, Alberta, Canada
🇨🇦
London Health Sciences Centre - University Hospital, London, Ontario, Canada

and more 15 locations

A Study of Aspirin and Clopidogrel in Patients With Idiopathic Pulmonary Arterial Hypertension

Phase 2

Completed

Conditions: Hypertension, Pulmonary

First Posted Date: 2005-03-10

Last Posted Date: 2005-06-24

Lead Sponsor: Kawut, Steven, MD

Target Recruit Count: 20

Registration Number: NCT00105209

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
Columbia University College of Physicians and Surgeons, New York, New York, United States

Aspirin in Treating Patients With Colorectal Cancer That Has Been Surgically Removed

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Other: placebo
Drug: aspirin

First Posted Date: 2004-08-31

Last Posted Date: 2016-07-04

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 635

Registration Number: NCT00002527

Locations: 🇺🇸
CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
CCOP - Carle Cancer Center, Urbana, Illinois, United States

and more 39 locations

Aggrenox Prevention of Access Stenosis

Phase 3

Completed

Conditions: Kidney Failure

Interventions: Drug: Aggrenox
Drug: Placebo

First Posted Date: 2003-08-13

Last Posted Date: 2017-09-19

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 649

Registration Number: NCT00067119

Locations: 🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 6 locations

Aspirin and/or Folic Acid in Preventing Recurrent Colorectal Polyps

Not Applicable

Conditions: Colorectal Cancer

First Posted Date: 2003-07-01

Last Posted Date: 2013-09-17

Lead Sponsor: Queen's Medical Center

Registration Number: NCT00033319

Locations: 🇬🇧
Antrim Hospital, Antrim, England, United Kingdom
🇬🇧
Glenfield Hospital, Leicester, England, United Kingdom
🇬🇧
Wythenshawe Hospital, Manchester, England, United Kingdom

and more 29 locations

Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)

Phase 2

Completed

Conditions: Ischemic Stroke

Interventions: Drug: Aspirin
Drug: tinzaparin sodium
Drug: eptifibatide

First Posted Date: 2003-05-26

Last Posted Date: 2013-02-04

Lead Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Target Recruit Count: 18

Registration Number: NCT00061373

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
Suburban Hospital, Bethesda, Maryland, United States
🇺🇸
Washington Hospital Center, Washington, District of Columbia, United States

Secondary Prevention of Small Subcortical Strokes Trial

Phase 3

Completed

Conditions: Cerebrovascular Accident
Hypertension

Interventions: Drug: aspirin
Other: Target of Blood Pressure
Drug: clopidogrel
Other: placebo

First Posted Date: 2003-04-24

Last Posted Date: 2013-04-04

Lead Sponsor: University of British Columbia

Target Recruit Count: 3020

Registration Number: NCT00059306

Locations: 🇺🇸
Ohio State University, Division of Stroke, Columbus, Ohio, United States
🇺🇸
Marshfield Clinic, Department of Neurology, Marshfield, Wisconsin, United States
🇺🇸
Metrohealth Medical Center, Cleveland, Ohio, United States

and more 59 locations

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: bicalutamide
Drug: Goserelin Acetate
Drug: docetaxel
Drug: Estramustine phosphate sodium
Drug: acetylsalicylic acid
Procedure: conventional surgery
Radiation: radiation therapy

First Posted Date: 2003-03-07

Last Posted Date: 2023-01-18

Lead Sponsor: UNICANCER

Target Recruit Count: 413

Registration Number: NCT00055731

Locations: 🇫🇷
Centre Paul Papin, Angers, France
🇫🇷
Hopital Saint Andre, Bordeaux, France
🇫🇷
Institut Bergonie, Bordeaux, France

and more 35 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy